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Abstract
Globally, early initiation of antiretroviral therapy for HIV led to a reduction in the estimated
mortality from cryptococcal meningitis (CCM) from 624,700 in 2009 to 181,100 in 2014.
However, CCM remains one of the leading causes of mortality among HIV infected patients
especially in sub-Saharan Africa where 75% of the deaths occur. Most of the studies evalu-
ating mortality have reported short-term mortality (at or before 10 weeks of therapy). We
determined mortality and associated factors among patients treated for CCM in the Crypto-
Dex trial (ISRCTN59144167) in Uganda, and the effect of dexamethasone adjunctive ther-
apy on mortality at two years. We conducted a retrospective cohort study between May
2017 and July 2017 to determine the long term survival (up to 2 years post-randomization)
of all patients who had been enrolled into the CryptoDex trial in Uganda. The CryptoDex trial
recruited between April 2013 and February 2015. We estimated mortality rates and deter-
mined factors affecting mortality at two years using Cox regression. The study followed up
211 participants, 127 (60.2%) of whom were male. Sixteen participants (7.58%) were diag-
nosed with HIV at the same admission when CCM was diagnosed. By two years following
randomization 127 (60%) participants had died, a mortality rate of 67 deaths per 100 per-
son-years. Mortality was associated with Glasgow coma score (GCS) below 15 (adjusted
Hazard ratio (aHR) 1.77, 95% CI: 1.02–2.44), p = 0.040; weight (aHR 0.97, per 1 Kg
increase; 95% CI: 0.94–0.99), p = 0.003; and presence of convulsions (aHR 2.31, 95% CI:
1.32–4.04), p = 0.004, while dexamethasone use and fungal burden had no effect. Long-
term mortality in CCM patients remains high even among patients receiving recommended
therapy. Strategies to improve long-term survival in CCM patients are urgently needed,
especially targeting those with reduced GCS, low weight, and convulsions.
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Author summary
With early initiation of ART among HIV infected patients, mortality from CCM has sig-
nificantly gone down. CCM however remains the second highest cause of mortality in
HIV, the highest burden being in sub-Saharan Africa where 75% of all deaths occur. Most
of the studies evaluating mortality have reported short-term mortality. We determined
mortality and associated factors among patients treated for CCM using recommended
therapy in the CryptoDex trial (ISRCTN59144167) in Uganda, and the effect of dexameth-
asone adjunctive therapy on mortality at two years. This was done by looking back at all
211 patients who had previously been enrolled into a trial of treatment for CCM (the
CryptoDex trial, which recruited patients between April 2013 and February 2015) and
determining their survival up to 2 years after they entered the study. This retrospective
cohort study was done between May 2017 and July 2017. 127 (60%) of the patients had
died by two years. Those with Glasgow coma score (GCS) below 15, those with lower
weight, and those that had convulsions were more likely to die, while dexamethasone use
and fungal burden did not affect mortality. Long-term mortality in CCM patients remains
high even among patients receiving recommended therapy. Strategies to improve long-
term survival in CCM patients are urgently needed, especially targeting those with
reduced GCS, low weight, and convulsions.
Introduction
Improvements in the management of HIV including early initiation of antiretroviral therapy
have reduced the incidence of opportunistic infections such as cryptococcal meningitis (CCM)
[1]. In 2009, there were an estimated 975,000 cases of CCM; by 2014, this had fallen to approxi-
mately 225,000. Similarly, the number of estimated deaths fell from 625,000 in 2009 to 180,000
in 2014 [2, 3]. Unfortunately, as these figures illustrate, the risk of death once CCM develops
changed little over those five years. CCM remains one of the leading causes of morbidity and
mortality among HIV positive patients, coming second to tuberculosis [2–4], and is responsi-
ble for 15% of all AIDS-related deaths globally[3].
The highest burden of morbidity and mortality from CCM occurs in sub-Saharan Africa
where there were an estimated 162,500 cases (73% of the global figure) with 135,900 deaths
(75% of the global figure) in 2014 [3]. Many of the studies evaluating mortality published so
far have included patients treated with best available, rather than guideline-recommended
therapy, and few studies report mortality rates beyond the period of consolidation therapy [5–
9]. This is relevant, because in many places the only available treatment has been fluconazole,
although gold standard treatment has been based around intravenous amphotericin. As such,
these studies may miss longer-term mortality effects that could be consequences of initial treat-
ment. For example, different initial treatments may have different effects on the risk of disease
relapse and disability, both of which may influence long-term survival [10].
Even so, the mortality on amphotericin-based therapy is high, reported to vary between
20% and 50% by 10 weeks from diagnosis. In addition to treatment, the risk of death has been
associated with factors such as elevated intracranial pressure, slower fungal clearance from
cerebrospinal fluid, and drug toxicities, amongst others [11–14]. Among the few studies that
determined longer-term mortality, Butler K et al found a mortality of 66% at two years from
treatment initiation among patients treated for CCM using recommended therapy in Mulago
hospital in Uganda. This study explored the effect of only a few variables on mortality and the
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model included patients with cryptococcal antigenaemia but without CCM [15]. The majority
of studies of treatment for CCM follow patients for between 3 and 6 months[14]. Up to this
point, determinants of outcome include measures of disease severity at baseline, such as fungal
burden (the amount of culturable yeast in cerebrospinal fluid), and treatment choice [14].
However, survival curves suggest that deaths may continue beyond this point for patients who
do not receive initial treatment with Flucytosine [14]. We wanted to better understand the
long term outcomes of cryptococcal meningitis in our country, and how this is influenced by
treatment and non-treatment factors among CCM patients, including those previously associ-
ated with short term outcome. Identifying patients at increased risk of late death, while they
are still engaged in care, may enable the development of strategies to improve their prognoses.
We determined two-year mortality and associated factors (including the effect of dexametha-
sone adjunctive therapy) among patients previously enrolled in the CryptoDex trial (Clinical
trial registration number ISRCTN59144167, PMID: 25391338) [16] in Uganda. The Crypto-
Dex trial was stopped early due to safety concerns [16].
Methodology
Ethics statement
The study was approved by the Makerere University School of Public Health Research and
Ethics Committee. Permission to use information from the CryptoDex database was acquired
following standard MRC/UVRI & LSHTM Uganda Research Unit data sharing policy available
at https://www.mrcuganda.org/publications/data-sharing-policy. Written informed consent
was obtained from all participants that had been exited from the CryptoDex trial before data
collection. For participants that had died, the next of kin provided consent.
Study design and setting
We conducted a retrospective cohort study among patients previously enrolled in the Crypto-
Dex trial in Uganda. The CryptoDex trial was a double-blind placebo-controlled phase III
study of adjunctive dexamethasone in HIV infected adults with Cryptococcal meningitis con-
ducted between April 2013 and February 2015 at thirteen sites in six countries in Asia and
Africa. The Ugandan sites included two research centres belonging to the Medical Research
Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medi-
cine Uganda Research Unit (MRC/UVRI & LSHTM Uganda Research Unit), located at
Masaka and Entebbe. Entebbe and Masaka are located 37 and 140 kilometres south-west of
Kampala city respectively. Participants enrolled at Masaka research centre were admitted to
Masaka Regional Referral Hospital and mainly came from rural settings that constitute the
hospital catchment area. Participants enrolled at Entebbe research centre were admitted to
Entebbe General Hospital and mainly came from semi-urban settings that serve as the catch-
ment area for the hospital.
CryptoDex subjects, their management and follow up
Participants recruited in the CryptoDex study were 18 years and above, had HIV infection, a
clinical syndrome consistent with CCM, i.e., one or more of fever, neck stiffness, severe head-
ache, altered consciousness amongst others, and microbiologically confirmed disease as indi-
cated by one or more of the following results: positive India ink staining of cerebrospinal fluid
(CSF), culture of Cryptococcus species from CSF or blood, or cryptococcal antigen detected in
CSF on cryptococcal antigen lateral flow assay (IMMY). Other components of the inclusion
and exclusion criteria may be accessed in the published trial protocol [16]. Eligible patients
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were randomised in a 1:1 ratio to either dexamethasone adjunctive therapy or placebo in addi-
tion to antifungal treatment with intravenous Amphotericin B (1 mg per kilogram per day)
and 800mg daily oral Fluconazole for 14 days (induction phase). This was followed by a con-
tinuation phase with 800mg daily fluconazole for eight weeks, and then a maintenance phase
with oral fluconazole 200mg daily. At the time, this was the regimen recommended by WHO
for settings where Flucytosine was not available [12]. Patients received either dexamethasone
or placebo for 6 weeks as follows: intravenous administration of 0.3 mg and 0.2 mg per kilo-
gram of body weight per day during the first and second weeks respectively, followed by oral
administration of 0.1 mg per kilogram per day during the third week, 3 mg per day during the
fourth week, 2 mg per day during the fifth week, and 1 mg per day during the sixth week. Par-
ticipants were followed up for six months after enrolment.
Study subjects and data collection for the current study
This study was conducted between May and July 2017: we collected data on all participants
enrolled in the CryptoDex trial in Uganda to establish their survival status by the end of two
years from randomisation. Data was collected using semi-structured questionnaires, which
were developed in English, translated to Luganda, and back-translated. These were standard-
ised and piloted before use to assess comprehensibility. Trained research assistants adminis-
tered the questionnaires. Information for participants who died while still in the CryptoDex
trial was already available in the study database. Information for those that died after exit was
acquired through a next of kin while living participants were contacted in person. Participants
were tracked using contact details previously collected while in the CryptoDex trial. One ses-
sion was organised with each participant or next of kin during which an interview was admin-
istered. Data collected was supplemented by that already available in the CryptoDex database.
Study variables
The outcome variable was death within two years after randomization in the CryptoDex trial.
Predictor variables tested included treatment arm (placebo or dexamethasone); demographic
characteristics (gender, age, and education measured as number of years in school); site, i.e.
Masaka (rural) or Entebbe (semi-urban); ART status, i.e. on or not on ART; previous history
of CCM, i.e., ever or never suffered from CCM; history of convulsions; Glasgow coma Score,
i.e., 15 or <15; presence or absence of confusion; weight; blindness (No light perception in
one or both eyes); blurred vision; hearing impairment (reduced hearing in one or both ears);
presence of convulsions (at or before randomisation); first lumbar puncture opening pressure;
yeast quantitative count in cerebrospinal fluid (CSF); and white blood cell count in CSF. Vari-
ables were chosen based on literature review.
Data analysis
Data was entered into a Microsoft Access database, cleaned and analysed in STATA (College
Station, TX, version 15.0). Frequencies and percentages were used to summarise categorical
variables while continuous variables were summarised using means (standard deviation) and /
or medians (interquartile ranges (IQR)). Time accrued was measured in person-years, esti-
mated as the difference in time from entry (Randomisation) to death or time of censor (com-
pletion of 2 years from randomisation or time last known to be alive). We estimated survival
using Kaplan-Meier (K-M) curves for the whole cohort and as per the intervention (Dexa-
methasone/placebo). We used Cox regression models to estimate overall mortality rate as well
as crude and adjusted mortality rates. Variables that had a likelihood ratio test (LRT) p-value
of 0.2 and below in the crude analysis were included in the multivariable Cox regression
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models. Variables were retained in the multivariable model if their inclusion resulted into a
better model than the model without the variable based on the LRT p-value (p-value<0.05)
using a stepwise building approach. A test of proportionality of hazards was conducted for the
variables evaluated individually and for the final model.
Results
�All patients were treated with 2 weeks of amphotericin B 1mg/kg daily and 2 weeks of flucon-
azole, 800mg/day followed by 8 weeks of fluconazole 800mg daily, then fluconazole 200mg/
day.
Baseline characteristics
Fig 1 is a flow diagram showing participants enrolled in the CryptoDex trial in Uganda and
mortality through two years from treatment initiation of therapy. Out of 323 patients screened
at the two sites in Uganda, 212 were found eligible for participation in the CryptoDex trial,
one died before randomisation, and 211 were randomised. Data for all randomised
Fig 1. Study flow diagram showing participants enrolled in the CryptoDex trial in Uganda and mortality through two years after
initiation of therapy.
https://doi.org/10.1371/journal.pntd.0008823.g001
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participants was used in this analysis (Fig 1). Of these, 127 participants (60.2%) were male. The
mean age (SD) was 36.4 years (8) and one hundred and five participants (49.8%) were rando-
mised to receive dexamethasone adjunctive therapy. Sixteen patients (7.6%) were diagnosed
with HIV on admission with CCM, while 195 (92.4%) were already known to be HIV positive
with 116 (59.5%) of these already on ART. The median last CD4 (IQR) done prior to enrol-
ment was 29 (7–71) cells/uL. Of all participants, 131 (65.5%) had CSF opening pressure
�18cm of CSF, and 118 (55.9%) had more than 1000 yeast cells per ml of CSF. Twenty-five
participants (11.8%) reported history of convulsions and fifty (23.7%) had haemoglobin counts
below 10mg/dl. The baseline characteristics are summarised in Table 1.
Mortality by two years
All models assessed passed the test of proportional hazards assumption. At two years from ini-
tiation of treatment for CCM, 127 patients had died (proportionate mortality of 60%), giving a
mortality rate of 67 deaths per 100 person-years after 190.7 person-years of follow up. The
mortality rate was 57 and 79 deaths per 100 person-years among patients that received placebo
and dexamethasone adjunctive therapy respectively. The median survival time was approxi-
mately 3 months. Basing on the Kaplan-Meier plot (Fig 2), mortality was highest during the
first 6 months. Fig 3 shows mortality by intervention.
Factors associated with mortality
Results from the univariate and multivariate analysis are summarised in Table 2.
Crude analysis. In the univariate analysis, the factors significantly associated with mortal-
ity included Glasgow coma score below 15 (HR 1.77, 95% CI: 1.20–2.61), p = 0.004; weight,
with the hazard of mortality reducing by a factor of 0.96 for every kilogram increase in weight
(HR 0.96, 95% CI: 0.94–0.98), p<0.001; haemoglobin count below 10g/dl (HR 1.51, 95% CI
1.03–2.22), p = 0.035; and presence of convulsions (HR 2.32, 95% CI: 1.45–3.71), p<0.001.
There was no association between mortality within two years and dexamethasone use (HR
1.22, 95% CI: 0.86–1.73), p = 0.264, although the CryptoDex study had been stopped early fol-
lowing an interim safety analysis because of evidence of increased rates of adverse events and
slower fungal clearance in patients receiving dexamethasone.
Adjusted analysis. From the multivariate analysis, the factors independently significantly
associated with mortality within the first two years following diagnosis were Glasgow coma
score below 15 (aHR 1.77, 95% CI: 1.02–2.44), p = 0.04; weight, with the hazard of mortality
decreasing by a factor of 0.97 for every kilogram increase in weight (aHR 0.97, 95% CI 0.94–
0.99), p = 0.003; and presence of convulsions (aHR 2.31, 95% CI: 1.32–4.04), p = 0.004. There
was no relationship between mortality at 2 years and gender, age, ART status at CCM diagno-
sis, haemoglobin count, or yeast quantitative count in CSF.
Discussion
By the end of two years of follow-up, 127 of the 211 study participants had died yielding 60%
proportionate mortality and an overall mortality rate of 67 deaths per 100 person-years. This
mortality rate contrasts markedly with that previously reported for Ugandan HIV patients
with CD4 counts similar to those of our patients, i.e., below 50cells/ml, of 6.73 deaths per 100
person-years [17]. However, we believe our finding is plausible since it is consistent with the
proportionate mortality of 66% reported by Butler et al from their study of patients with cryp-
tococcal meningitis from Mulago Hospital, Uganda [15].
Apart from cryptococcal meningitis itself, other potential contributors to mortality during
this period include drug-related toxicities, immune reconstitution syndrome (IRIS), morbidity
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associated with residual disability, and other infections, since patients are still severely
immune-suppressed [18]. Like others, we found that most deaths did occur within the first 6
months following diagnosis [14, 19]. This suggests that efforts to improve early treatment of
cryptococcal disease are likely to deliver the best long-term gains.
Unfortunately, there is a dearth of therapeutic options for cryptococcal meningitis. Crypto-
coccal meningitis continues to be managed using drugs that were discovered more than 60
years ago, whose use is also associated with multiple toxicities [20], while 30–40% of patients
Table 1. Baseline characteristics of study participants at randomisation in the CryptoDex trial.
Variable Treatment Total 211
Placebo (N = 106) Dexamethasone (N = 105)
Level N % n %
Gender Male 60 56.6 67 63.8 127
Female 46 43.4 38 36.2 84
Age 18–30 Years 40 37.7 28 26.7 68
31–39 Years 33 31.1 44 41.9 77
40+ Years 33 31.1 33 31.4 66
Education �7 Years 65 73.9 52 59.1 117
>7 Years 23 26.1 36 40.9 59
Site Entebbe 43 40.6 43 41.0 86
Masaka 63 59.4 62 59.0 125
HIV diagnosis known before No 10 9.4 6 5.7 16
Yes 96 90.6 99 94.3 195
Previous CCM No 98 92.5 95 90.5 193
Yes 8 7.5 10 9.5 18
History of Convulsion No 90 84.9 95 91.3 185
Yes 16 15.1 9 8.7 25
Glasgow coma Score 15 83 78.3 82 78.1 165
<15 23 21.7 23 21.9 46
Confusion No 65 61.9 64 61.9 129
Yes 40 38.1 41 38.1 81
Mean Weight kg (SD) 51.2 (9.59) 50.7 (10.61) 51.0 (10.09)
Blindness� No 96 99.0 96 99.0 192
Yes 1 1.0 1 1.0 2
Blurred vision No 77 79.4 75 77.3 152
Yes 20 20.6 22 22.7 42
Hearing Impairment No 88 88.9 86 86.9 174
Yes 11 11.1 13 13.1 24
CSF Opening Pressure cm/CSF �18 37 36.6 32 32.3 69
>18 64 63.4 67 67.7 131
Yeast CFUs per ml of CSF �1000 45 42.5 48 45.7 93
>1000 61 57.5 57 54.3 118
CSF white-cell count cells/mm3 <5 2 2.0 0 0.0 2
�5 97 98.0 99 100.0 196
Haemoglobin g/dl �10 79 74.5 82 78.1 161
<10 27 25.5 23 21.9 50
Abbreviations: SD, Standard; HIV, Human immunodeficiency virus; CFUs, Colony-forming units; CCM. Cryptococcal meningitis; g/dl, grams/decilitre.
�No light perception in one or more eyes.
https://doi.org/10.1371/journal.pntd.0008823.t001
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fail to attain CSF sterilization [14, 19, 21]. There has been little real impact on mortality in the
last 20 years. Recent efforts examining drug repurposing and adjunctive therapy have been dis-
appointing [18, 22]. We therefore agree with previous researchers that alternative and comple-
mentary approaches for the management of CCM still need to be investigated to curb
mortality [11, 18]. Flucytosine remains expensive (>$120 per day) and unlicensed in most
countries in sub-Saharan Africa including Uganda. The most practical intervention remains
early HIV testing and intensive screening for CCM using the available Cryptococcal antigen
tests which enable identification of asymptomatic antigenaemia a median of 22 days before
meningitis sets in [23, 24]. It has been estimated that screening and pre-emptively treating peo-
ple with positive antigenaemia in Uganda would cost only 15% of the cost of meningitis treat-
ment, with more than 40% better long-term survival [15].
Fig 2. Kaplan-Meier plot showing survival of participants in the first 2 years of enrolment.
https://doi.org/10.1371/journal.pntd.0008823.g002
Fig 3. Kaplan-Meier plot showing survival of participants in the first 2 years of enrolment categorised per intervention.
https://doi.org/10.1371/journal.pntd.0008823.g003
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Table 2. Mortality rates and effect of different factors on mortality at two years.
Variable Unadjusted Adjusted�
Level Number of deaths/Person years at
risk
Mortality per 100 person-
yrs.
HR P Value HR(95% CI) P-value
Overall 127/191 67
Intervention� Placebo 61/107 57





Gender Male 75/114 66
Female 52/77 68 1.04 (0.73–
1.48)
0.845
Age 18–30 years 38/72 53
31–39 years 46/64 75 1.25 (0.82–
1.92)
0.297
40+ years 41/55 74 1.29 (0.83–
2.01)
0.254
Education �7 Years 70/105 67
>7 Years 33/62 53 0.84 (0.56–
1.27)
0.415
Site� Entebbe 57/69 83





HIV known before Baseline No 7/19 38
Yes 120/172 70 1.55 (0.72–
3.32)
0.259
On ARVS Yes 66/117 56





Previous CCM No 115/175 67
Yes 12/16 76 1.12 (0.62–
2.03)
0.705
History of Convulsion� No 105/180 58





Glasgow coma Score� 15 91/166 55





Confusion No 73/125 59
Yes 53/66 81 1.28 (0.90–
1.83)
0.166





Blurred vision No 85/150 57
Yes 26/37 71 1.15 (0.74–
1.78)
0.541
Hearing Impairment No 100/167 60
Yes 15/21 73 1.11 (0.64–
1.91)
0.706
CSF Opening Pressure� cm/
CSF
�18 46/54 85





Yeast CFUs per ml of CSF �1000 53/91 58
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Mortality was not significantly different between patients treated with adjunctive dexa-
methasone therapy and those on placebo. This result is similar to findings from the CryptoDex
study where no difference in mortality was observed at 10 weeks and 6 months [18]. This is
perhaps not surprising given that the CryptoDex study was stopped after the enrolment of 451
patients following an interim safety analysis because of evidence of accumulating harm in
patients receiving dexamethasone, in the form of increased rates of adverse events and slower
fungal clearance. However, it is reassuring that deaths did not continue to accumulate as a con-
sequence of the receipt of dexamethasone. It is however clear that dexamethasone neither
improves short term or longer-term survival from CCM. The 2018 WHO guidelines on cryp-
tococcal treatment recommend against use of corticosteroids during the induction treatment
phase for CCM [25].
It had been hypothesised in the CryptoDex study that dexamethasone would improve out-
comes by reducing both intracranial pressure and inflammatory complications, and decreasing
the incidence of IRIS. Analysis done on CSF from a subset of patients in the CryptoDex study
revealed that there was a downregulation of pro-inflammatory cytokines among dexametha-
sone recipients [26]. This could explain the absence of benefit.
Recently data has emerged from the ACTA trial of combination antifungal therapy for
CCM in Africa, suggesting that despite good sterilising power, longer courses of amphotericin
(2 versus 1 weeks) may be harmful to patients [27]. In this study, the best outcomes were seen
in patients receiving amphotericin for one week, in combination with Flucytosine. Patients
receiving two weeks of amphotericin had more adverse events, and worse survival (although
the latter did not reach statistical significance). While the sterilising effect of one and two-week
amphotericin regimes over the first two weeks seemed similar, it will be important to see
whether there is any effect on long term survival. Differences in induction therapy appear to
be able to influence long term outcomes, certainly up to 6 months after diagnosis [14].
We found that higher weight was associated with a reduced risk of mortality. Other studies
among CCM patients have reported a similar finding, though this was after much shorter peri-
ods of follow up [19, 28]. An association between greater weight and improved survival is plau-
sible since it is likely that the lighter patients had more advanced HIV disease and less
physiological reserve. Scherzer R et al previously reported that lower muscle mass was associ-
ated with increased risk of mortality among HIV patients in general [29].
Presence of convulsions was also associated with increased risk of mortality. A similar find-
ing has previously been reported in previous studies [30, 31]. Convulsions may be associated
with more severe disease and/or other effects in the brain that could increase the risk of mor-
tality. The possibility of other disease manifestations such as cryptococcomas, or comorbidities
that can cause convulsions cannot be entirely ruled out in our patients because, unfortunately,
Table 2. (Continued)
Variable Unadjusted Adjusted�
Level Number of deaths/Person years at
risk
Mortality per 100 person-
yrs.
HR P Value HR(95% CI) P-value
Haemoglobin� g/dl �10 90/157 57





Abbreviations: SD, Standard deviation; ART, Antiretroviral therapy; CFUs, Colony-forming units; H2O, Water; CI, Confidence interval; HIV, Human
immunodeficiency virus; kg, kilogram; g/dl, grams/decilitre.
�Variables included in the final model.
https://doi.org/10.1371/journal.pntd.0008823.t002
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advanced investigatory modalities like CT scans are not readily available in settings such as
our own.
Although not statistically significant, participants from Masaka were less likely to die than
those from Entebbe. Masaka is a rural setting, while Entebbe and its catchment area is mainly
semi-urban. Possibly, the social set up of people in rural settings in Masaka enabled closer
social support by family members for those that were sick or recovering from disease com-
pared to those from Entebbe. Presence of social support has previously been reported to be
associated with better health outcomes [32, 33].
We did not find that factors previously reported by others to be associated with short-term
mortality such as white blood cell count in CSF, haemoglobin count, age, and altered mental
status, affected longer-term mortality in our study [19, 28]. Such associations may diminish in
importance as patients survive for longer periods.
We were unable to measure other factors that could have a bearing on long-term mortality
such as antifungal treatment resistance. Antifungal susceptibility is considered to be relevant
to treatment response in relapsed disease, but susceptibility testing at the point of first diagno-
sis appears to have little utility; few data exist on which to make a judgement regarding its abil-
ity to determine long term outcomes [34]. It would have been good to explore the effect of
CD4 counts on mortality. Unfortunately, CD4 counts were not measured at baseline in the
CryptoDex study. The requirement was for participants to report their last CD4 counts at
enrolment. Many had forgotten/had no record or presented those done a long time prior. It
would have also been good to see the effect of baseline viral loads on mortality. These were
however not tested in the CryptoDex trial.
Conclusion
This study shows that long-term mortality in CCM patients, even among those receiving rec-
ommended therapy remains high. Adjunctive therapy with dexamethasone does not have a
significant effect on mortality at two years, while wasted patients, those who present with
impaired consciousness as defined by Glasgow Coma score <15, and those with histories of
convulsions, are more likely to die.
We recommend extensive implementation of Cryptococcal screening in low resource settings
to prevent CCM whose management remains a daunting and challenging experience. There is a
pressing need to develop better treatment for those patients who present with the disease.
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